Silence Therapeutics plc (LON:SLN) had its target price hoisted by Canaccord Genuity from GBX 233 ($3.04) to GBX 249 ($3.25) in a research report sent to investors on Tuesday morning. The firm currently has a buy rating on the stock.
Silence Therapeutics plc (LON:SLN) opened at 124.5625 on Tuesday. Silence Therapeutics plc has a 12-month low of GBX 96.63 and a 12-month high of GBX 235.25. The stock’s market cap is GBX 86.95 million. The firm’s 50 day moving average price is GBX 114.17 and its 200-day moving average price is GBX 116.44.
Silence Therapeutics plc Company Profile
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.